Literature DB >> 30840036

Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitation-Contradictory or Complementary?

Gilbert H L Tang1, Subodh Verma2, Deepak L Bhatt3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30840036     DOI： 10.1001/jamacardio.2019.0204

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  16 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

Authors:  Steven P Marso; Neil R Poulter; Steven E Nissen; Michael A Nauck; Bernard Zinman; Gilbert H Daniels; Stuart Pocock; William M Steinberg; Richard M Bergenstal; Johannes F E Mann; Lasse Steen Ravn; Kirstine Brown Frandsen; Alan C Moses; John B Buse
Journal:  Am Heart J       Date:  2013-10-02       Impact factor: 4.749

3.  Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.

Authors:  Subodh Verma; Lawrence A Leiter; C David Mazer; Stephen C Bain; John Buse; Steve Marso; Michael Nauck; Bernard Zinman; Heidrun Bosch-Traberg; Søren Rasmussen; Marie M Michelsen; Deepak L Bhatt
Journal:  Circulation       Date:  2018-10-09       Impact factor: 29.690

4.  Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

Authors:  Deepak L Bhatt; Ph Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; John Gregson; Stuart J Pocock; Christie M Ballantyne
Journal:  J Am Coll Cardiol       Date:  2019-03-18       Impact factor: 24.094

5.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

6.  Economic Evaluation of Complete Revascularization for Patients with Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Garry R Barton; Lisa Irvine; Marcus Flather; Gerry P McCann; Nick Curzen; Anthony H Gershlick
Journal:  Value Health       Date:  2017-03-22       Impact factor: 5.725

7.  Modelling recurrent events: a tutorial for analysis in epidemiology.

Authors:  Leila D A F Amorim; Jianwen Cai
Journal:  Int J Epidemiol       Date:  2014-12-09       Impact factor: 7.196

8.  Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.

Authors:  Sabina A Murphy; Christopher P Cannon; Stephen D Wiviott; Carolyn H McCabe; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2009-12-15       Impact factor: 24.094

9.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Authors:  Adrian F Hernandez; Jennifer B Green; Salim Janmohamed; Ralph B D'Agostino; Christopher B Granger; Nigel P Jones; Lawrence A Leiter; Anne E Rosenberg; Kristina N Sigmon; Matthew C Somerville; Karl M Thorpe; John J V McMurray; Stefano Del Prato
Journal:  Lancet       Date:  2018-10-02       Impact factor: 79.321

10.  A systematic comparison of recurrent event models for application to composite endpoints.

Authors:  Ann-Kathrin Ozga; Meinhard Kieser; Geraldine Rauch
Journal:  BMC Med Res Methodol       Date:  2018-01-04       Impact factor: 4.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.